NanoViricides filed a pre-funded common stock purchase warrant for 200,000 shares with an exercise date of May 18, 2026, issued under a Securities Purchase Agreement dated May 15, 2026. The warrant allows holders to purchase common stock at a specified exercise price, providing the company with potential capital raising and shareholder dilution implications.